idarubicin has been researched along with Bilirubinemia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Amadori, S; de Witte, T; Halkes, CJ; Karrasch, M; Marie, JP; Meert, L; Meloni, G; Muus, P; Rapion, J; Suciu, S; Vignetti, M; Willemze, R | 1 |
| Corallo, CE; Coutsouvelis, J | 1 |
1 trial(s) available for idarubicin and Bilirubinemia
| Article | Year |
|---|---|
Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): p
Topics: Adenine Nucleotides; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Consolidation Chemotherapy; Cytarabine; Fatigue; Female; Gastrointestinal Diseases; Humans; Hydroxyurea; Hyperbilirubinemia; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Risk; Treatment Outcome | 2014 |
1 other study(ies) available for idarubicin and Bilirubinemia
| Article | Year |
|---|---|
The management of prolonged, isolated hyperbilirubinemia following cytarabine-based chemotherapy for acute myeloid leukaemia.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Humans; Hyperbilirubinemia; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Time Factors | 2009 |